Moderna's COVID Vaccine Was a Historic Success. Could Its Cancer Vaccine Be Even Bigger?
Key PointsModerna's recent success in a phase 3 clinical trial for its personalized cancer vaccine was a breakthrough.
Moderna's COVID-19 vaccine, Spikevax, has generated peak sales of $18.4 billion in 2022 and is on track for around $50 billion in lifetime sales. This mRNA-based vaccine has proven to be a game-changer in the biotech industry. However, the company's recent success in developing a personalized cancer vaccine, intismeran autogene, could surpass these achievements.
Moderna's cancer vaccine, known as intismeran autogene, has demonstrated exceptional results in phase 3 clinical trials. This innovative therapy, which tailors the vaccine to an individual's unique cancer antigens, has sent the company's stock soaring. This breakthrough could potentially revolutionize cancer treatment and generate substantial revenue for Moderna in the future.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
